nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—Protein urine present—Capecitabine—esophageal cancer	0.00294	0.00479	CcSEcCtD
Imiquimod—Cyst—Methotrexate—esophageal cancer	0.00292	0.00476	CcSEcCtD
Imiquimod—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.0029	0.00473	CcSEcCtD
Imiquimod—Herpes simplex—Capecitabine—esophageal cancer	0.00284	0.00464	CcSEcCtD
Imiquimod—Nasal congestion—Cisplatin—esophageal cancer	0.00283	0.00462	CcSEcCtD
Imiquimod—Ulcer—Capecitabine—esophageal cancer	0.00277	0.00452	CcSEcCtD
Imiquimod—Bone pain—Capecitabine—esophageal cancer	0.00273	0.00446	CcSEcCtD
Imiquimod—Inflammation—Capecitabine—esophageal cancer	0.0027	0.0044	CcSEcCtD
Imiquimod—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00263	0.00429	CcSEcCtD
Imiquimod—Herpes zoster—Methotrexate—esophageal cancer	0.00259	0.00422	CcSEcCtD
Imiquimod—Influenza like illness—Capecitabine—esophageal cancer	0.00254	0.00415	CcSEcCtD
Imiquimod—Fungal infection—Methotrexate—esophageal cancer	0.00253	0.00412	CcSEcCtD
Imiquimod—Skin ulcer—Methotrexate—esophageal cancer	0.0025	0.00408	CcSEcCtD
Imiquimod—Skin exfoliation—Capecitabine—esophageal cancer	0.0025	0.00408	CcSEcCtD
Imiquimod—Face oedema—Cisplatin—esophageal cancer	0.00249	0.00406	CcSEcCtD
Imiquimod—Irritability—Cisplatin—esophageal cancer	0.00246	0.00402	CcSEcCtD
Imiquimod—Breast disorder—Cisplatin—esophageal cancer	0.00233	0.0038	CcSEcCtD
Imiquimod—Proteinuria—Methotrexate—esophageal cancer	0.00222	0.00362	CcSEcCtD
Imiquimod—Protein urine present—Methotrexate—esophageal cancer	0.00219	0.00357	CcSEcCtD
Imiquimod—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00218	0.00355	CcSEcCtD
Imiquimod—Sweating increased—Cisplatin—esophageal cancer	0.00217	0.00354	CcSEcCtD
Imiquimod—Swelling—Capecitabine—esophageal cancer	0.00216	0.00351	CcSEcCtD
Imiquimod—Pancytopenia—Cisplatin—esophageal cancer	0.00212	0.00345	CcSEcCtD
Imiquimod—Herpes simplex—Methotrexate—esophageal cancer	0.00212	0.00345	CcSEcCtD
Imiquimod—Ulcer—Methotrexate—esophageal cancer	0.00206	0.00336	CcSEcCtD
Imiquimod—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00206	0.00336	CcSEcCtD
Imiquimod—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.00201	0.00329	CcSEcCtD
Imiquimod—Inflammation—Methotrexate—esophageal cancer	0.00201	0.00328	CcSEcCtD
Imiquimod—Atrial fibrillation—Capecitabine—esophageal cancer	0.00201	0.00327	CcSEcCtD
Imiquimod—Purpura—Capecitabine—esophageal cancer	0.00197	0.00322	CcSEcCtD
Imiquimod—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00196	0.0032	CcSEcCtD
Imiquimod—Arthritis—Capecitabine—esophageal cancer	0.00196	0.00319	CcSEcCtD
Imiquimod—Vaginal inflammation—Methotrexate—esophageal cancer	0.00195	0.00318	CcSEcCtD
Imiquimod—Myocardial infarction—Cisplatin—esophageal cancer	0.00195	0.00318	CcSEcCtD
Imiquimod—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00195	0.00318	CcSEcCtD
Imiquimod—Cardiac failure—Capecitabine—esophageal cancer	0.00195	0.00318	CcSEcCtD
Imiquimod—Lethargy—Capecitabine—esophageal cancer	0.00194	0.00316	CcSEcCtD
Imiquimod—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00194	0.00316	CcSEcCtD
Imiquimod—Conjunctivitis—Cisplatin—esophageal cancer	0.00193	0.00315	CcSEcCtD
Imiquimod—Pain in extremity—Capecitabine—esophageal cancer	0.0019	0.0031	CcSEcCtD
Imiquimod—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00188	0.00307	CcSEcCtD
Imiquimod—Migraine—Capecitabine—esophageal cancer	0.00187	0.00305	CcSEcCtD
Imiquimod—Skin exfoliation—Methotrexate—esophageal cancer	0.00186	0.00304	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—LGALS3—esophageal cancer	0.00185	0.00482	CbGpPWpGaD
Imiquimod—Vaginal infection—Methotrexate—esophageal cancer	0.00184	0.003	CcSEcCtD
Imiquimod—CYP1A2—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00184	0.00481	CbGpPWpGaD
Imiquimod—Face oedema—Capecitabine—esophageal cancer	0.00184	0.00299	CcSEcCtD
Imiquimod—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00183	0.00479	CbGpPWpGaD
Imiquimod—Irritability—Capecitabine—esophageal cancer	0.00181	0.00296	CcSEcCtD
Imiquimod—Urinary retention—Capecitabine—esophageal cancer	0.00181	0.00295	CcSEcCtD
Imiquimod—TLR7—Immune System—MAP3K3—esophageal cancer	0.00177	0.00463	CbGpPWpGaD
Imiquimod—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00176	0.0046	CbGpPWpGaD
Imiquimod—Urinary tract disorder—Cisplatin—esophageal cancer	0.00176	0.00287	CcSEcCtD
Imiquimod—Connective tissue disorder—Cisplatin—esophageal cancer	0.00175	0.00286	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—HMGB1—esophageal cancer	0.00175	0.00457	CbGpPWpGaD
Imiquimod—Urethral disorder—Cisplatin—esophageal cancer	0.00175	0.00285	CcSEcCtD
Imiquimod—Pulmonary oedema—Methotrexate—esophageal cancer	0.00174	0.00283	CcSEcCtD
Imiquimod—Visual impairment—Cisplatin—esophageal cancer	0.00172	0.0028	CcSEcCtD
Imiquimod—Breast disorder—Capecitabine—esophageal cancer	0.00172	0.0028	CcSEcCtD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00168	0.00439	CbGpPWpGaD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00168	0.00439	CbGpPWpGaD
Imiquimod—Eye disorder—Cisplatin—esophageal cancer	0.00167	0.00272	CcSEcCtD
Imiquimod—Tinnitus—Cisplatin—esophageal cancer	0.00166	0.00271	CcSEcCtD
Imiquimod—Lymphadenopathy—Methotrexate—esophageal cancer	0.00166	0.00271	CcSEcCtD
Imiquimod—Flushing—Cisplatin—esophageal cancer	0.00166	0.0027	CcSEcCtD
Imiquimod—Influenza—Capecitabine—esophageal cancer	0.00164	0.00268	CcSEcCtD
Imiquimod—TLR8—Immune System—ELMO1—esophageal cancer	0.00164	0.00429	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—ACTB—esophageal cancer	0.00164	0.00428	CbGpPWpGaD
Imiquimod—Immune system disorder—Cisplatin—esophageal cancer	0.00161	0.00263	CcSEcCtD
Imiquimod—Mediastinal disorder—Cisplatin—esophageal cancer	0.00161	0.00262	CcSEcCtD
Imiquimod—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00161	0.0042	CbGpPWpGaD
Imiquimod—Sweating increased—Capecitabine—esophageal cancer	0.0016	0.00261	CcSEcCtD
Imiquimod—Arrhythmia—Cisplatin—esophageal cancer	0.00159	0.0026	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—B2M—esophageal cancer	0.00158	0.00413	CbGpPWpGaD
Imiquimod—Bronchitis—Capecitabine—esophageal cancer	0.00158	0.00258	CcSEcCtD
Imiquimod—Alopecia—Cisplatin—esophageal cancer	0.00158	0.00257	CcSEcCtD
Imiquimod—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00157	0.00411	CbGpPWpGaD
Imiquimod—Pancytopenia—Capecitabine—esophageal cancer	0.00156	0.00255	CcSEcCtD
Imiquimod—CYP1A2—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00156	0.00407	CbGpPWpGaD
Imiquimod—Malnutrition—Cisplatin—esophageal cancer	0.00155	0.00253	CcSEcCtD
Imiquimod—Erythema—Cisplatin—esophageal cancer	0.00155	0.00253	CcSEcCtD
Imiquimod—Dysuria—Capecitabine—esophageal cancer	0.00154	0.00251	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00153	0.00249	CcSEcCtD
Imiquimod—TLR7—Immune System—CTSC—esophageal cancer	0.00151	0.00394	CbGpPWpGaD
Imiquimod—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.0015	0.00245	CcSEcCtD
Imiquimod—Photosensitivity reaction—Capecitabine—esophageal cancer	0.0015	0.00245	CcSEcCtD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.0015	0.00392	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CFL1—esophageal cancer	0.00148	0.00387	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—PIK3CA—esophageal cancer	0.00147	0.00385	CbGpPWpGaD
Imiquimod—Infestation NOS—Capecitabine—esophageal cancer	0.00147	0.00239	CcSEcCtD
Imiquimod—Infestation—Capecitabine—esophageal cancer	0.00147	0.00239	CcSEcCtD
Imiquimod—Depression—Capecitabine—esophageal cancer	0.00146	0.00238	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00145	0.00237	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—ABL1—esophageal cancer	0.00145	0.00378	CbGpPWpGaD
Imiquimod—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00144	0.00236	CcSEcCtD
Imiquimod—Lethargy—Methotrexate—esophageal cancer	0.00144	0.00236	CcSEcCtD
Imiquimod—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00144	0.00236	CcSEcCtD
Imiquimod—Ill-defined disorder—Cisplatin—esophageal cancer	0.00144	0.00235	CcSEcCtD
Imiquimod—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00144	0.00234	CcSEcCtD
Imiquimod—Myocardial infarction—Capecitabine—esophageal cancer	0.00144	0.00234	CcSEcCtD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—PIK3CA—esophageal cancer	0.00143	0.00374	CbGpPWpGaD
Imiquimod—Urinary tract infection—Capecitabine—esophageal cancer	0.00142	0.00232	CcSEcCtD
Imiquimod—Conjunctivitis—Capecitabine—esophageal cancer	0.00142	0.00232	CcSEcCtD
Imiquimod—CYP1A2—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.00142	0.00371	CbGpPWpGaD
Imiquimod—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00142	0.00371	CbGpPWpGaD
Imiquimod—TLR8—Immune System—LGALS3—esophageal cancer	0.00142	0.00371	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.00142	0.0037	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—esophageal cancer	0.00142	0.0037	CbGpPWpGaD
Imiquimod—Malaise—Cisplatin—esophageal cancer	0.0014	0.00228	CcSEcCtD
Imiquimod—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00139	0.00226	CcSEcCtD
Imiquimod—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00139	0.00362	CbGpPWpGaD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00138	0.00361	CbGpPWpGaD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00138	0.00359	CbGpPWpGaD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00137	0.00357	CbGpPWpGaD
Imiquimod—Irritability—Methotrexate—esophageal cancer	0.00135	0.0022	CcSEcCtD
Imiquimod—Convulsion—Cisplatin—esophageal cancer	0.00135	0.00219	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—HMGB1—esophageal cancer	0.00133	0.00346	CbGpPWpGaD
Imiquimod—Myalgia—Cisplatin—esophageal cancer	0.00132	0.00216	CcSEcCtD
Imiquimod—Haemoglobin—Capecitabine—esophageal cancer	0.00132	0.00216	CcSEcCtD
Imiquimod—Rhinitis—Capecitabine—esophageal cancer	0.00132	0.00215	CcSEcCtD
Imiquimod—Anxiety—Cisplatin—esophageal cancer	0.00132	0.00215	CcSEcCtD
Imiquimod—Haemorrhage—Capecitabine—esophageal cancer	0.00132	0.00215	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00131	0.00214	CcSEcCtD
Imiquimod—Discomfort—Cisplatin—esophageal cancer	0.00131	0.00213	CcSEcCtD
Imiquimod—Pharyngitis—Capecitabine—esophageal cancer	0.00131	0.00213	CcSEcCtD
Imiquimod—Urinary tract disorder—Capecitabine—esophageal cancer	0.0013	0.00212	CcSEcCtD
Imiquimod—CYP1A2—Tryptophan metabolism—ALDH2—esophageal cancer	0.0013	0.00339	CbGpPWpGaD
Imiquimod—Connective tissue disorder—Capecitabine—esophageal cancer	0.00129	0.00211	CcSEcCtD
Imiquimod—Urethral disorder—Capecitabine—esophageal cancer	0.00129	0.0021	CcSEcCtD
Imiquimod—TLR8—lung—esophageal cancer	0.00128	0.323	CbGeAlD
Imiquimod—Breast disorder—Methotrexate—esophageal cancer	0.00128	0.00209	CcSEcCtD
Imiquimod—Oedema—Cisplatin—esophageal cancer	0.00127	0.00207	CcSEcCtD
Imiquimod—Visual impairment—Capecitabine—esophageal cancer	0.00127	0.00207	CcSEcCtD
Imiquimod—Infection—Cisplatin—esophageal cancer	0.00126	0.00205	CcSEcCtD
Imiquimod—TLR8—Immune System—ACTB—esophageal cancer	0.00126	0.00329	CbGpPWpGaD
Imiquimod—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00126	0.00329	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ELMO1—esophageal cancer	0.00124	0.00325	CbGpPWpGaD
Imiquimod—Erythema multiforme—Capecitabine—esophageal cancer	0.00124	0.00203	CcSEcCtD
Imiquimod—Nervous system disorder—Cisplatin—esophageal cancer	0.00124	0.00203	CcSEcCtD
Imiquimod—Tachycardia—Cisplatin—esophageal cancer	0.00124	0.00202	CcSEcCtD
Imiquimod—Skin disorder—Cisplatin—esophageal cancer	0.00123	0.00201	CcSEcCtD
Imiquimod—TLR8—Immune System—PTPN2—esophageal cancer	0.00123	0.00321	CbGpPWpGaD
Imiquimod—Eye disorder—Capecitabine—esophageal cancer	0.00123	0.002	CcSEcCtD
Imiquimod—Tinnitus—Capecitabine—esophageal cancer	0.00123	0.002	CcSEcCtD
Imiquimod—Hyperhidrosis—Cisplatin—esophageal cancer	0.00123	0.002	CcSEcCtD
Imiquimod—Flushing—Capecitabine—esophageal cancer	0.00122	0.00199	CcSEcCtD
Imiquimod—TLR8—Immune System—B2M—esophageal cancer	0.00122	0.00318	CbGpPWpGaD
Imiquimod—Anorexia—Cisplatin—esophageal cancer	0.00121	0.00197	CcSEcCtD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00121	0.00315	CbGpPWpGaD
Imiquimod—Angiopathy—Capecitabine—esophageal cancer	0.00119	0.00195	CcSEcCtD
Imiquimod—Immune system disorder—Capecitabine—esophageal cancer	0.00119	0.00194	CcSEcCtD
Imiquimod—Mediastinal disorder—Capecitabine—esophageal cancer	0.00119	0.00193	CcSEcCtD
Imiquimod—Chills—Capecitabine—esophageal cancer	0.00118	0.00192	CcSEcCtD
Imiquimod—Arrhythmia—Capecitabine—esophageal cancer	0.00118	0.00192	CcSEcCtD
Imiquimod—Alopecia—Capecitabine—esophageal cancer	0.00116	0.0019	CcSEcCtD
Imiquimod—Pancytopenia—Methotrexate—esophageal cancer	0.00116	0.00189	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00115	0.00188	CcSEcCtD
Imiquimod—Mental disorder—Capecitabine—esophageal cancer	0.00115	0.00188	CcSEcCtD
Imiquimod—TLR8—Immune System—PSME1—esophageal cancer	0.00115	0.003	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PSME2—esophageal cancer	0.00115	0.003	CbGpPWpGaD
Imiquimod—Malnutrition—Capecitabine—esophageal cancer	0.00115	0.00187	CcSEcCtD
Imiquimod—Erythema—Capecitabine—esophageal cancer	0.00115	0.00187	CcSEcCtD
Imiquimod—Dysuria—Methotrexate—esophageal cancer	0.00114	0.00187	CcSEcCtD
Imiquimod—Paraesthesia—Cisplatin—esophageal cancer	0.00114	0.00186	CcSEcCtD
Imiquimod—TLR8—Immune System—HSPA5—esophageal cancer	0.00114	0.00297	CbGpPWpGaD
Imiquimod—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00114	0.00185	CcSEcCtD
Imiquimod—Dyspnoea—Cisplatin—esophageal cancer	0.00113	0.00184	CcSEcCtD
Imiquimod—Erectile dysfunction—Methotrexate—esophageal cancer	0.00113	0.00184	CcSEcCtD
Imiquimod—TLR7—Immune System—CFL1—esophageal cancer	0.00112	0.00293	CbGpPWpGaD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00112	0.00293	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—PIK3CA—esophageal cancer	0.00112	0.00292	CbGpPWpGaD
Imiquimod—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00112	0.00182	CcSEcCtD
Imiquimod—Back pain—Capecitabine—esophageal cancer	0.00111	0.00181	CcSEcCtD
Imiquimod—TLR8—Immune System—CALR—esophageal cancer	0.0011	0.00288	CbGpPWpGaD
Imiquimod—Decreased appetite—Cisplatin—esophageal cancer	0.0011	0.0018	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—ABL1—esophageal cancer	0.0011	0.00287	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—TLR4—esophageal cancer	0.0011	0.00287	CbGpPWpGaD
Imiquimod—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00109	0.00178	CcSEcCtD
Imiquimod—Infestation—Methotrexate—esophageal cancer	0.00109	0.00178	CcSEcCtD
Imiquimod—Infestation NOS—Methotrexate—esophageal cancer	0.00109	0.00178	CcSEcCtD
Imiquimod—Depression—Methotrexate—esophageal cancer	0.00109	0.00177	CcSEcCtD
Imiquimod—Pain—Cisplatin—esophageal cancer	0.00108	0.00177	CcSEcCtD
Imiquimod—CYP1A2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00108	0.00282	CbGpPWpGaD
Imiquimod—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00108	0.00176	CcSEcCtD
Imiquimod—TLR7—Immune System—LGALS3—esophageal cancer	0.00108	0.00281	CbGpPWpGaD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00107	0.00279	CbGpPWpGaD
Imiquimod—TLR8—Immune System—FBXW7—esophageal cancer	0.00107	0.00279	CbGpPWpGaD
Imiquimod—Ill-defined disorder—Capecitabine—esophageal cancer	0.00106	0.00173	CcSEcCtD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00106	0.00277	CbGpPWpGaD
Imiquimod—Conjunctivitis—Methotrexate—esophageal cancer	0.00106	0.00173	CcSEcCtD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00105	0.00275	CbGpPWpGaD
Imiquimod—Feeling abnormal—Cisplatin—esophageal cancer	0.00104	0.0017	CcSEcCtD
Imiquimod—Malaise—Capecitabine—esophageal cancer	0.00103	0.00168	CcSEcCtD
Imiquimod—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00103	0.00168	CcSEcCtD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00103	0.00269	CbGpPWpGaD
Imiquimod—Syncope—Capecitabine—esophageal cancer	0.00103	0.00167	CcSEcCtD
Imiquimod—TLR8—Immune System—HMGB1—esophageal cancer	0.00102	0.00266	CbGpPWpGaD
Imiquimod—Palpitations—Capecitabine—esophageal cancer	0.00101	0.00165	CcSEcCtD
Imiquimod—Loss of consciousness—Capecitabine—esophageal cancer	0.00101	0.00164	CcSEcCtD
Imiquimod—Body temperature increased—Cisplatin—esophageal cancer	0.001	0.00163	CcSEcCtD
Imiquimod—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.001	0.00261	CbGpPWpGaD
Imiquimod—Cough—Capecitabine—esophageal cancer	0.000999	0.00163	CcSEcCtD
Imiquimod—Hypertension—Capecitabine—esophageal cancer	0.000989	0.00161	CcSEcCtD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000986	0.00258	CbGpPWpGaD
Imiquimod—Haemoglobin—Methotrexate—esophageal cancer	0.000984	0.00161	CcSEcCtD
Imiquimod—CYP1A2—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000983	0.00257	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.000983	0.00257	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—esophageal cancer	0.000983	0.00257	CbGpPWpGaD
Imiquimod—Haemorrhage—Methotrexate—esophageal cancer	0.000979	0.0016	CcSEcCtD
Imiquimod—Arthralgia—Capecitabine—esophageal cancer	0.000975	0.00159	CcSEcCtD
Imiquimod—Myalgia—Capecitabine—esophageal cancer	0.000975	0.00159	CcSEcCtD
Imiquimod—Chest pain—Capecitabine—esophageal cancer	0.000975	0.00159	CcSEcCtD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000973	0.00254	CbGpPWpGaD
Imiquimod—Pharyngitis—Methotrexate—esophageal cancer	0.000972	0.00158	CcSEcCtD
Imiquimod—Anxiety—Capecitabine—esophageal cancer	0.000971	0.00158	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000968	0.00158	CcSEcCtD
Imiquimod—Urinary tract disorder—Methotrexate—esophageal cancer	0.000967	0.00158	CcSEcCtD
Imiquimod—Discomfort—Capecitabine—esophageal cancer	0.000963	0.00157	CcSEcCtD
Imiquimod—Urethral disorder—Methotrexate—esophageal cancer	0.00096	0.00157	CcSEcCtD
Imiquimod—TLR7—Immune System—ACTB—esophageal cancer	0.000954	0.00249	CbGpPWpGaD
Imiquimod—Dry mouth—Capecitabine—esophageal cancer	0.000953	0.00155	CcSEcCtD
Imiquimod—CYP1A2—Phase II conjugation—GSTO1—esophageal cancer	0.000947	0.00247	CbGpPWpGaD
Imiquimod—Visual impairment—Methotrexate—esophageal cancer	0.000944	0.00154	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—CASP8—esophageal cancer	0.000941	0.00246	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CREBBP—esophageal cancer	0.000937	0.00245	CbGpPWpGaD
Imiquimod—Oedema—Capecitabine—esophageal cancer	0.000934	0.00152	CcSEcCtD
Imiquimod—Hypersensitivity—Cisplatin—esophageal cancer	0.000934	0.00152	CcSEcCtD
Imiquimod—TLR7—Immune System—PTPN2—esophageal cancer	0.000932	0.00243	CbGpPWpGaD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000931	0.00243	CbGpPWpGaD
Imiquimod—Infection—Capecitabine—esophageal cancer	0.000928	0.00151	CcSEcCtD
Imiquimod—Erythema multiforme—Methotrexate—esophageal cancer	0.000926	0.00151	CcSEcCtD
Imiquimod—CYP1A2—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000924	0.00241	CbGpPWpGaD
Imiquimod—TLR7—Immune System—B2M—esophageal cancer	0.000922	0.00241	CbGpPWpGaD
Imiquimod—CYP1A2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00092	0.0024	CbGpPWpGaD
Imiquimod—Shock—Capecitabine—esophageal cancer	0.000919	0.0015	CcSEcCtD
Imiquimod—Nervous system disorder—Capecitabine—esophageal cancer	0.000916	0.00149	CcSEcCtD
Imiquimod—Eye disorder—Methotrexate—esophageal cancer	0.000915	0.00149	CcSEcCtD
Imiquimod—Tinnitus—Methotrexate—esophageal cancer	0.000913	0.00149	CcSEcCtD
Imiquimod—Tachycardia—Capecitabine—esophageal cancer	0.000912	0.00149	CcSEcCtD
Imiquimod—Asthenia—Cisplatin—esophageal cancer	0.00091	0.00148	CcSEcCtD
Imiquimod—Skin disorder—Capecitabine—esophageal cancer	0.000908	0.00148	CcSEcCtD
Imiquimod—Hyperhidrosis—Capecitabine—esophageal cancer	0.000903	0.00147	CcSEcCtD
Imiquimod—Anorexia—Capecitabine—esophageal cancer	0.000891	0.00145	CcSEcCtD
Imiquimod—Angiopathy—Methotrexate—esophageal cancer	0.000888	0.00145	CcSEcCtD
Imiquimod—Immune system disorder—Methotrexate—esophageal cancer	0.000884	0.00144	CcSEcCtD
Imiquimod—Mediastinal disorder—Methotrexate—esophageal cancer	0.000882	0.00144	CcSEcCtD
Imiquimod—Chills—Methotrexate—esophageal cancer	0.000879	0.00143	CcSEcCtD
Imiquimod—TLR8—lymph node—esophageal cancer	0.000876	0.221	CbGeAlD
Imiquimod—TLR7—Immune System—PSME2—esophageal cancer	0.000871	0.00227	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PSME1—esophageal cancer	0.000871	0.00227	CbGpPWpGaD
Imiquimod—Diarrhoea—Cisplatin—esophageal cancer	0.000867	0.00141	CcSEcCtD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000866	0.00226	CbGpPWpGaD
Imiquimod—Alopecia—Methotrexate—esophageal cancer	0.000865	0.00141	CcSEcCtD
Imiquimod—TLR7—Immune System—HSPA5—esophageal cancer	0.000863	0.00225	CbGpPWpGaD
Imiquimod—Mental disorder—Methotrexate—esophageal cancer	0.000858	0.0014	CcSEcCtD
Imiquimod—Erythema—Methotrexate—esophageal cancer	0.000852	0.00139	CcSEcCtD
Imiquimod—Malnutrition—Methotrexate—esophageal cancer	0.000852	0.00139	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000851	0.00139	CcSEcCtD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00085	0.00222	CbGpPWpGaD
Imiquimod—Insomnia—Capecitabine—esophageal cancer	0.000845	0.00138	CcSEcCtD
Imiquimod—TLR8—Immune System—ABL1—esophageal cancer	0.000843	0.0022	CbGpPWpGaD
Imiquimod—Paraesthesia—Capecitabine—esophageal cancer	0.000839	0.00137	CcSEcCtD
Imiquimod—TLR7—Immune System—CALR—esophageal cancer	0.000836	0.00218	CbGpPWpGaD
Imiquimod—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000835	0.00218	CbGpPWpGaD
Imiquimod—Dyspnoea—Capecitabine—esophageal cancer	0.000833	0.00136	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—TLR4—esophageal cancer	0.000831	0.00217	CbGpPWpGaD
Imiquimod—Back pain—Methotrexate—esophageal cancer	0.000824	0.00134	CcSEcCtD
Imiquimod—Dyspepsia—Capecitabine—esophageal cancer	0.000823	0.00134	CcSEcCtD
Imiquimod—Decreased appetite—Capecitabine—esophageal cancer	0.000812	0.00132	CcSEcCtD
Imiquimod—TLR7—Immune System—FBXW7—esophageal cancer	0.000808	0.00211	CbGpPWpGaD
Imiquimod—TLR7—lung—esophageal cancer	0.000808	0.204	CbGeAlD
Imiquimod—TLR8—Innate Immune System—BCL2—esophageal cancer	0.000808	0.00211	CbGpPWpGaD
Imiquimod—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000807	0.00132	CcSEcCtD
Imiquimod—Vomiting—Cisplatin—esophageal cancer	0.000806	0.00131	CcSEcCtD
Imiquimod—Fatigue—Capecitabine—esophageal cancer	0.000806	0.00131	CcSEcCtD
Imiquimod—Rash—Cisplatin—esophageal cancer	0.000799	0.0013	CcSEcCtD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000799	0.00209	CbGpPWpGaD
Imiquimod—Pain—Capecitabine—esophageal cancer	0.000799	0.0013	CcSEcCtD
Imiquimod—Dermatitis—Cisplatin—esophageal cancer	0.000799	0.0013	CcSEcCtD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000796	0.00208	CbGpPWpGaD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000795	0.00208	CbGpPWpGaD
Imiquimod—Ill-defined disorder—Methotrexate—esophageal cancer	0.000791	0.00129	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—ERBB2—esophageal cancer	0.000785	0.00205	CbGpPWpGaD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000784	0.00205	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HMGB1—esophageal cancer	0.000772	0.00202	CbGpPWpGaD
Imiquimod—Feeling abnormal—Capecitabine—esophageal cancer	0.00077	0.00126	CcSEcCtD
Imiquimod—Malaise—Methotrexate—esophageal cancer	0.000769	0.00125	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.000766	0.002	CbGpPWpGaD
Imiquimod—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000764	0.00125	CcSEcCtD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000761	0.00199	CbGpPWpGaD
Imiquimod—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000759	0.00198	CbGpPWpGaD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000758	0.00198	CbGpPWpGaD
Imiquimod—Nausea—Cisplatin—esophageal cancer	0.000753	0.00123	CcSEcCtD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000751	0.00196	CbGpPWpGaD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000747	0.00195	CbGpPWpGaD
Imiquimod—Cough—Methotrexate—esophageal cancer	0.000744	0.00121	CcSEcCtD
Imiquimod—Urticaria—Capecitabine—esophageal cancer	0.000742	0.00121	CcSEcCtD
Imiquimod—Abdominal pain—Capecitabine—esophageal cancer	0.000739	0.0012	CcSEcCtD
Imiquimod—Body temperature increased—Capecitabine—esophageal cancer	0.000739	0.0012	CcSEcCtD
Imiquimod—Convulsion—Methotrexate—esophageal cancer	0.000739	0.0012	CcSEcCtD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000737	0.00193	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.000734	0.00192	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.000731	0.00191	CbGpPWpGaD
Imiquimod—Myalgia—Methotrexate—esophageal cancer	0.000726	0.00118	CcSEcCtD
Imiquimod—Chest pain—Methotrexate—esophageal cancer	0.000726	0.00118	CcSEcCtD
Imiquimod—Arthralgia—Methotrexate—esophageal cancer	0.000726	0.00118	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000721	0.00118	CcSEcCtD
Imiquimod—Discomfort—Methotrexate—esophageal cancer	0.000717	0.00117	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—CASP8—esophageal cancer	0.000713	0.00186	CbGpPWpGaD
Imiquimod—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000713	0.00186	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CREBBP—esophageal cancer	0.00071	0.00185	CbGpPWpGaD
Imiquimod—Infection—Methotrexate—esophageal cancer	0.000691	0.00113	CcSEcCtD
Imiquimod—Hypersensitivity—Capecitabine—esophageal cancer	0.000688	0.00112	CcSEcCtD
Imiquimod—Nervous system disorder—Methotrexate—esophageal cancer	0.000682	0.00111	CcSEcCtD
Imiquimod—Skin disorder—Methotrexate—esophageal cancer	0.000676	0.0011	CcSEcCtD
Imiquimod—Hyperhidrosis—Methotrexate—esophageal cancer	0.000673	0.0011	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—CDKN1A—esophageal cancer	0.000671	0.00175	CbGpPWpGaD
Imiquimod—Asthenia—Capecitabine—esophageal cancer	0.00067	0.00109	CcSEcCtD
Imiquimod—Anorexia—Methotrexate—esophageal cancer	0.000663	0.00108	CcSEcCtD
Imiquimod—Pruritus—Capecitabine—esophageal cancer	0.000661	0.00108	CcSEcCtD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000656	0.00171	CbGpPWpGaD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000644	0.00168	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	0.000641	0.00167	CbGpPWpGaD
Imiquimod—Diarrhoea—Capecitabine—esophageal cancer	0.000639	0.00104	CcSEcCtD
Imiquimod—TLR7—Immune System—ABL1—esophageal cancer	0.000639	0.00167	CbGpPWpGaD
Imiquimod—TLR8—Immune System—TLR4—esophageal cancer	0.000639	0.00167	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—EP300—esophageal cancer	0.000638	0.00167	CbGpPWpGaD
Imiquimod—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000634	0.00103	CcSEcCtD
Imiquimod—Insomnia—Methotrexate—esophageal cancer	0.000629	0.00103	CcSEcCtD
Imiquimod—Paraesthesia—Methotrexate—esophageal cancer	0.000625	0.00102	CcSEcCtD
Imiquimod—Dyspnoea—Methotrexate—esophageal cancer	0.00062	0.00101	CcSEcCtD
Imiquimod—Somnolence—Methotrexate—esophageal cancer	0.000618	0.00101	CcSEcCtD
Imiquimod—Dizziness—Capecitabine—esophageal cancer	0.000618	0.00101	CcSEcCtD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000617	0.00161	CbGpPWpGaD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000613	0.0016	CbGpPWpGaD
Imiquimod—Dyspepsia—Methotrexate—esophageal cancer	0.000612	0.000999	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—BCL2—esophageal cancer	0.000612	0.0016	CbGpPWpGaD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000606	0.00158	CbGpPWpGaD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000605	0.00158	CbGpPWpGaD
Imiquimod—Decreased appetite—Methotrexate—esophageal cancer	0.000605	0.000986	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000601	0.000979	CcSEcCtD
Imiquimod—Fatigue—Methotrexate—esophageal cancer	0.0006	0.000978	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	0.000596	0.00156	CbGpPWpGaD
Imiquimod—Pain—Methotrexate—esophageal cancer	0.000595	0.00097	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—ERBB2—esophageal cancer	0.000595	0.00155	CbGpPWpGaD
Imiquimod—Vomiting—Capecitabine—esophageal cancer	0.000594	0.000969	CcSEcCtD
Imiquimod—Rash—Capecitabine—esophageal cancer	0.000589	0.000961	CcSEcCtD
Imiquimod—Dermatitis—Capecitabine—esophageal cancer	0.000589	0.00096	CcSEcCtD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000588	0.00153	CbGpPWpGaD
Imiquimod—Headache—Capecitabine—esophageal cancer	0.000585	0.000955	CcSEcCtD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000585	0.00153	CbGpPWpGaD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000577	0.00151	CbGpPWpGaD
Imiquimod—Feeling abnormal—Methotrexate—esophageal cancer	0.000573	0.000935	CcSEcCtD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000569	0.00149	CbGpPWpGaD
Imiquimod—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000569	0.000928	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000564	0.00147	CbGpPWpGaD
Imiquimod—Nausea—Capecitabine—esophageal cancer	0.000555	0.000905	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	0.000554	0.00145	CbGpPWpGaD
Imiquimod—Urticaria—Methotrexate—esophageal cancer	0.000553	0.000901	CcSEcCtD
Imiquimod—TLR7—lymph node—esophageal cancer	0.000553	0.139	CbGeAlD
Imiquimod—Abdominal pain—Methotrexate—esophageal cancer	0.00055	0.000897	CcSEcCtD
Imiquimod—Body temperature increased—Methotrexate—esophageal cancer	0.00055	0.000897	CcSEcCtD
Imiquimod—TLR8—Immune System—CASP8—esophageal cancer	0.000548	0.00143	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	0.000546	0.00143	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CREBBP—esophageal cancer	0.000546	0.00143	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—EGFR—esophageal cancer	0.000544	0.00142	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000539	0.00141	CbGpPWpGaD
Imiquimod—Hypersensitivity—Methotrexate—esophageal cancer	0.000513	0.000836	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—CDKN1A—esophageal cancer	0.000508	0.00133	CbGpPWpGaD
Imiquimod—Asthenia—Methotrexate—esophageal cancer	0.000499	0.000814	CcSEcCtD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000497	0.0013	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000495	0.00129	CbGpPWpGaD
Imiquimod—Pruritus—Methotrexate—esophageal cancer	0.000492	0.000803	CcSEcCtD
Imiquimod—TLR7—Immune System—TLR4—esophageal cancer	0.000484	0.00126	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—EP300—esophageal cancer	0.000484	0.00126	CbGpPWpGaD
Imiquimod—Diarrhoea—Methotrexate—esophageal cancer	0.000476	0.000776	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—PIK3CA—esophageal cancer	0.000472	0.00123	CbGpPWpGaD
Imiquimod—TLR8—Immune System—BCL2—esophageal cancer	0.00047	0.00123	CbGpPWpGaD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000467	0.00122	CbGpPWpGaD
Imiquimod—Dizziness—Methotrexate—esophageal cancer	0.00046	0.00075	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.00046	0.0012	CbGpPWpGaD
Imiquimod—TLR8—Immune System—ERBB2—esophageal cancer	0.000457	0.00119	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000454	0.00118	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	0.000452	0.00118	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.000443	0.00116	CbGpPWpGaD
Imiquimod—Vomiting—Methotrexate—esophageal cancer	0.000442	0.000721	CcSEcCtD
Imiquimod—Rash—Methotrexate—esophageal cancer	0.000439	0.000715	CcSEcCtD
Imiquimod—Dermatitis—Methotrexate—esophageal cancer	0.000438	0.000715	CcSEcCtD
Imiquimod—Headache—Methotrexate—esophageal cancer	0.000436	0.000711	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	0.00043	0.00112	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000428	0.00112	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	0.000425	0.00111	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000422	0.0011	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CASP8—esophageal cancer	0.000415	0.00109	CbGpPWpGaD
Imiquimod—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000414	0.00108	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CREBBP—esophageal cancer	0.000414	0.00108	CbGpPWpGaD
Imiquimod—Nausea—Methotrexate—esophageal cancer	0.000413	0.000674	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—EGFR—esophageal cancer	0.000412	0.00108	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	0.000402	0.00105	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CDKN1A—esophageal cancer	0.000391	0.00102	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000387	0.00101	CbGpPWpGaD
Imiquimod—TLR8—Immune System—EP300—esophageal cancer	0.000372	0.000971	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000368	0.000962	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000368	0.000962	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PIK3CA—esophageal cancer	0.000358	0.000934	CbGpPWpGaD
Imiquimod—TLR7—Immune System—BCL2—esophageal cancer	0.000356	0.000931	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000349	0.00091	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ERBB2—esophageal cancer	0.000346	0.000905	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	0.000342	0.000894	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000338	0.000882	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000331	0.000866	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.00033	0.000862	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000328	0.000856	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	0.000322	0.00084	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000321	0.000839	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000317	0.000829	CbGpPWpGaD
Imiquimod—TLR8—Immune System—EGFR—esophageal cancer	0.000317	0.000827	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000314	0.00082	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000314	0.00082	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000311	0.000811	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDKN1A—esophageal cancer	0.000296	0.000773	CbGpPWpGaD
Imiquimod—TLR7—Immune System—EP300—esophageal cancer	0.000282	0.000736	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PIK3CA—esophageal cancer	0.000275	0.000718	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000264	0.00069	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00026	0.00068	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000248	0.000649	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000245	0.00064	CbGpPWpGaD
Imiquimod—TLR7—Immune System—EGFR—esophageal cancer	0.00024	0.000627	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000223	0.000582	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PIK3CA—esophageal cancer	0.000208	0.000544	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000195	0.000508	CbGpPWpGaD
Imiquimod—CYP1A2—digestive system—esophageal cancer	0.000174	0.044	CbGeAlD
Imiquimod—CYP1A2—Metabolism—BLVRB—esophageal cancer	0.000173	0.000452	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SLC52A3—esophageal cancer	0.000173	0.000452	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000155	0.000404	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CA1—esophageal cancer	0.000147	0.000384	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SLC10A2—esophageal cancer	0.000147	0.000384	CbGpPWpGaD
Imiquimod—CYP1A2—lung—esophageal cancer	0.000146	0.0367	CbGeAlD
Imiquimod—CYP1A2—Metabolism—CA2—esophageal cancer	0.000134	0.000351	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000133	0.000349	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000133	0.000349	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000131	0.000343	CbGpPWpGaD
Imiquimod—CYP3A4—digestive system—esophageal cancer	0.000126	0.0318	CbGeAlD
Imiquimod—CYP1A2—Metabolism—PLCE1—esophageal cancer	0.000125	0.000326	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ADH7—esophageal cancer	0.000125	0.000326	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000124	0.000323	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CA1—esophageal cancer	0.000113	0.000296	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000113	0.000296	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ADH1B—esophageal cancer	0.00011	0.000286	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—TYMP—esophageal cancer	0.000105	0.000274	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CA2—esophageal cancer	0.000104	0.000271	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP26A1—esophageal cancer	0.000102	0.000266	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ALOX15—esophageal cancer	9.93e-05	0.000259	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PLCE1—esophageal cancer	9.65e-05	0.000252	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ADH7—esophageal cancer	9.65e-05	0.000252	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—TPI1—esophageal cancer	9.47e-05	0.000247	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTO1—esophageal cancer	9.47e-05	0.000247	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ALDOB—esophageal cancer	9.08e-05	0.000237	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GAPDH—esophageal cancer	8.74e-05	0.000228	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CRABP1—esophageal cancer	8.66e-05	0.000226	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ADH1B—esophageal cancer	8.46e-05	0.000221	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GNG7—esophageal cancer	8.24e-05	0.000215	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—TYMP—esophageal cancer	8.08e-05	0.000211	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP26A1—esophageal cancer	7.86e-05	0.000205	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ALDH2—esophageal cancer	7.72e-05	0.000202	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ALOX15—esophageal cancer	7.66e-05	0.0002	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTT1—esophageal cancer	7.35e-05	0.000192	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—TPI1—esophageal cancer	7.31e-05	0.000191	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTO1—esophageal cancer	7.31e-05	0.000191	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP2A6—esophageal cancer	7.26e-05	0.00019	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.23e-05	0.000189	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ALDOB—esophageal cancer	7.01e-05	0.000183	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ENO1—esophageal cancer	6.88e-05	0.00018	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTGS1—esophageal cancer	6.88e-05	0.00018	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PSME1—esophageal cancer	6.78e-05	0.000177	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PSME2—esophageal cancer	6.78e-05	0.000177	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GAPDH—esophageal cancer	6.75e-05	0.000176	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CRABP1—esophageal cancer	6.69e-05	0.000175	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GNG7—esophageal cancer	6.36e-05	0.000166	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.96e-05	0.000156	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.92e-05	0.000155	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP1B1—esophageal cancer	5.85e-05	0.000153	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.67e-05	0.000148	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.6e-05	0.000146	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP19A1—esophageal cancer	5.5e-05	0.000144	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ENO1—esophageal cancer	5.31e-05	0.000139	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.31e-05	0.000139	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PSME1—esophageal cancer	5.23e-05	0.000137	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PSME2—esophageal cancer	5.23e-05	0.000137	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—HMOX1—esophageal cancer	5.02e-05	0.000131	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.93e-05	0.000129	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ABCB1—esophageal cancer	4.82e-05	0.000126	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.52e-05	0.000118	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.25e-05	0.000111	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.88e-05	0.000101	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.72e-05	9.71e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.64e-05	9.52e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.22e-05	8.41e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NOS3—esophageal cancer	2.88e-05	7.53e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.64e-05	6.89e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.49e-05	6.49e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NOS3—esophageal cancer	2.23e-05	5.81e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—EP300—esophageal cancer	2.19e-05	5.73e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.04e-05	5.32e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—EP300—esophageal cancer	1.69e-05	4.42e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.62e-05	4.24e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.25e-05	3.27e-05	CbGpPWpGaD
